Novo's Wegovy shown to cut obesity in young children in trial
Summarised from 2 outlets · Updated 16 Nov, 15:37 · Archive
Novo's weight-loss drug Wegovy significantly reduced body mass index in children aged 6 to under 12 during a late-stage trial.
Novo released full results on Monday from a late-stage trial showing Wegovy reduced body mass index by an estimated 19.7 percentage points more than placebo at 68 weeks in children aged 6 to under 12. Among children receiving the drug, BMI fell 17.4 per cent, whilst rising 2.2 per cent in those receiving placebo.
All 167 children in the study received lifestyle modifications throughout the trial, including a reduced-calorie diet and increased physical activity. When evaluating all children including those who discontinued treatment, Wegovy lowered BMI by an estimated 16.2 percentage points more than placebo.
Wegovy is already approved for obesity treatment in children 12 and older, but no medications are currently approved for those under 12. Dr Andrea Traina, Novo's medical director lead of obesity, described childhood obesity as 'a very significant disease burden in this very young patient population'. The latest results suggest Wegovy could fill the treatment gap for younger children.

How it is being reported
- Six-year-olds: Novo’s new frontier for weight-loss drugsWegovy helped almost 8 in 10 children as young as 6 lose more than 10% of their BMI in trialFinancial Times · 16 Nov, 15:00
- Novo says Wegovy injection lowers BMI and obesity rates in children in trialWegovy is already approved to treat obesity in children ages 12 and older, but there are currently no approved medications for those under 12.CNBC · 16 Nov, 15:00
In this story: Novo · Wegovy · World Obesity Federation
This summary was written by AI from the headlines and standfirsts above, and states as fact only what at least two outlets report. How we use AI · Report a problem · Corrections log
Comments (0)